Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Eli Lilly 22.974, Roche 17.1305.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Eli Lilly vs Roche Net Worth and Market Cap
Eli Lilly (LLY) and Roche (RHHBY) are peers in GLP-1. Eli Lilly reported revenue of $23.0B as of Q2 2026, compared with $34.3B for Roche. Roche leads on revenue.
Eli Lilly's gross margin is 85.8% versus 71.7% for Roche. Eli Lilly's net margin is 30.9% versus 17.9% for Roche.
Key differences
- Revenue growth on the same quarter a year earlier: Eli Lilly +47.7% (Q2 2026), Roche -4.2% (Q4 2025).
- Eli Lilly keeps more of its revenue as operating profit: a 54.2% operating margin, against 23.2% at Roche.
- Eli Lilly's KPIs on Sterling include Cardiometabolic Manufacturing Capex Announcements by Site (Cumulative) and Foundayo Quarterly Revenue.
- Roche's KPIs on Sterling include Carmot Asset Pipeline: CT-388, CT-996, CT-868 Trial Readout Timeline and CT-868 (Acmopatide) Discontinuation.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Eli Lilly, Roche.| Metric | Eli Lilly | Roche |
|---|---|---|
| Market Cap | - | - |
| Revenue | $22.97B | $34.26B |
| Cost of Revenue | $3.27B | $9.68B |
| Gross Profit | $19.71B | $24.58B |
| Operating Income | $12.46B | $7.96B |
| Net Income | $7.09B | $6.13B |
| R&D Expense | $3.82B | $7.48B |
| Earnings Per Share | $7.94 | $0.95 |
| Gross Margin | 85.8% | 71.7% |
| Operating Margin | 54.2% | 23.2% |
| Net Profit Margin | 30.9% | 17.9% |
| Free Cash Flow | $7.76B | $10.67B |
| Cumulative Free Cash Flow | $109.66B | $299.34B |
| Operating Cash Flow | $10.69B | $13.12B |
| Cash & Equivalents | $8.89B | $6.32B |